指南与共识慢阻肺

中国慢性阻塞性肺疾病诊治指南(2026年修订版)

[Chinese guidelines for the diagnosis and management of chronic obstructive pulmonary disease (2026 revision)].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-10-26

本指南由中华医学会呼吸病学分会慢阻肺学组与中国医师协会呼吸医师分会慢阻肺工作委员会制定。指南基于近五年证据更新慢阻肺定义、筛查、诊断评估、稳定期与急性加重期管理及合并症等内容。采用GRADE方法为主,对22个临床问题形成推荐意见。

要点

  • 推荐主动机会性筛查以改善慢阻肺早期诊断。
  • 初始药物治疗需结合症状、急性加重风险、肺功能、合并症及血嗜酸粒细胞计数。
  • 血嗜酸粒细胞≥300细胞/μl且反复加重者可考虑三联吸入治疗或生物治疗。

核心结论

  • 指南旨在促进慢阻肺早期识别、规范诊治和综合管理,降低中国慢阻肺疾病负担。

研究设计与样本

  • 由中华医学会呼吸病学分会慢阻肺学组和中国医师协会呼吸医师分会慢阻肺工作委员会制定。
  • 主要采用GRADE方法评估证据确定性并形成推荐,辅以牛津循证医学中心证据分级。
  • 围绕22个临床问题制定推荐意见。

主要发现

  • 推荐对高风险人群开展主动和机会性病例发现以改善早期诊断。
  • 初始评估应包括症状负担、急性加重风险、气流受限严重程度、合并症及血嗜酸粒细胞计数等。
  • 随访期治疗调整应围绕持续性呼吸困难和急性加重两个可治疗特质。

关键数值与推荐

  • 血嗜酸粒细胞≥300细胞/μl时,推荐三联吸入治疗(ICS+LABA+LAMA)。
  • 每年≥1次中重度急性加重、血嗜酸粒细胞≥300细胞/μl或随访≥100细胞/μl、有哮喘史或哮喘样特征是加用ICS的指征。
  • 推荐每年接种流感疫苗,推荐PPSV23定期接种,易感者可选择PCV20或PCV21。
  • 症状可用mMRC呼吸困难量表或慢阻肺评估测试(CAT)评估,两者结果可能不一致。

临床怎么用

  • 所有慢阻肺患者均应积极提供戒烟干预。
  • 应根据吸气流量、手口协调能力和吸入能力等选择合适吸入装置并进行培训。
  • 稳定期无绝对禁忌者应尽早开始肺康复,急性加重患者住院期间及出院后应早期提供肺康复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Chinese guidelines for the diagnosis and management of chronic obstructive pulmonary disease (2026 revision) were developed by the Chronic Obstructive Pulmonary Disease Groups of the Chinese Thoracic Society and the Chinese Association of Chest Physicians. Building on the 2021 edition, this revision incorporates evidence published over the past five years and experience from COPD prevention and management in China, and provides comprehensive updates on disease definition, etiology and pathogenesis, case finding, diagnosis and comprehensive assessment, stable COPD management, diagnosis and treatment of acute exacerbations, comorbidity management, and future research directions. The guideline primarily applies the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, supplemented by the Oxford Centre for Evidence-Based Medicine Levels of Evidence, to assess the certainty of evidence and develop recommendations. It offers practical recommendations for the diagnosis and management of COPD across 22 clinical questions. It aims to promote early identification, standardized diagnosis and treatment, and comprehensive management of COPD, and therefore to improve the standardized care and reduce the disease burden of COPD in China.The 22 key clinical questions and corresponding recommendations are summarized as follows.Question 1: Given the current underdiagnosis of COPD, which strategies can improve early diagnosis?Recommendation 1: We recommend active and opportunistic case finding to identify individuals at high risk of COPD and facilitate early diagnosis. (1B/strong recommendation)Question 2: Which parameters should be assessed when selecting initial pharmacotherapy for patients with COPD?Recommendation 2: Patients with COPD should undergo individualized assessment based on symptom burden and exacerbation risk and be classified into groups A, B, or E. Additional assessments should include the severity of airflow obstruction on pulmonary function testing, comorbidities, and biomarkers such as the peripheral blood eosinophil count. (2B/strong recommendation)Question 3: How should the mMRC and CAT scores be used for symptom assessment in the ABE classification?Recommendation 3: Symptoms of COPD should be assessed using the modified Medical Research Council (mMRC) dyspnea scale and/or the COPD Assessment Test (CAT). Results from the two instruments may be discordant: the mMRC scale focuses on dyspnea, whereas the CAT is more suitable for a comprehensive assessment of multiple symptoms. (2B/strong recommendation)Question 4: Should chest CT be included in the initial assessment of COPD?Recommendation 4: Chest imaging should be included in the initial assessment of COPD, with chest computed tomography (CT) preferred. (2B/conditional recommendation)Question 5: What are the key preventive measures targeting exposure to risk factors?Recommendation 5: Smoking cessation interventions should be actively provided to all patients with COPD. Clean fuels, effective ventilation, nonpolluting stoves, and similar measures are recommended to reduce harmful environmental exposures; occupational protection should also be strengthened to avoid continued exposure to potential irritants. (1A/strong recommendation)Question 6: How should vaccination be recommended for patients with COPD?Recommendation 6: Annual influenza vaccination is recommended. Regular pneumococcal vaccination with PPSV23 is also recommended, with PCV20 or PCV21 as options for susceptible individuals; the specific pneumococcal vaccination schedule should follow product-specific prescribing information. (1A/strong recommendation). Vaccination against respiratory syncytial virus (RSV), tetanus, diphtheria, and acellular pertussis (Tdap), and herpes zoster is suggested. (1A/conditional recommendation)Question 7: How should initial pharmacotherapy be selected according to the ABE classification and the peripheral blood eosinophil count?Recommendation 7: Initial pharmacotherapy should be selected according to symptoms, exacerbation risk, and the peripheral blood eosinophil count. For patients in group E, regimens that reduce the risk of future exacerbations should be prioritized. When the peripheral blood eosinophil count is ≥300 cells/μl, triple inhaled therapy[inhaled corticosteroids(ICS) plus long-acting β2 agonists (LABA) plus long-acting muscarinic antagonists(LAMA)] is recommended to achieve a state of low disease activity characterized by freedom from exacerbations. (1B/strong recommendation)Question 8: What are the indications for adding an ICS to long-acting bronchodilator therapy?Recommendation 8: The addition of an ICS to long-acting bronchodilator therapy is recommended for patients with COPD who have any of the following features: (1)≥1 moderate or severe COPD exacerbation per year; (2) a blood eosinophil count ≥300 cells/μl, or ≥100 cells/μl during follow-up assessment; or (3) a history of asthma or concomitant asthma-like features. (1B/strong recommendation)Question 9: How should a standardized pathway for follow-up assessment and pharmacological treatment adjustment be established for patients with stable COPD?Recommendation 9: During follow-up pharmacotherapy, treatment adjustment should be guided by two core treatable traits: persistent dyspnea and the occurrence of exacerbations. For patients with persistently poor symptom control, bronchodilator therapy should be optimized stepwise after inhaler technique, adherence, and the effects of comorbidities have been assessed. For patients who continue to experience exacerbations, the addition, continuation, or cautious withdrawal of ICS should be guided by the current regimen and peripheral blood eosinophil count. Biologic therapy is appropriate for selected high-risk populations. (1B/strong recommendation)Question 10: How should treatment be optimized and adjusted for patients already receiving ICS+LABA therapy?Recommendation 10: Patients receiving ICS+LABA may continue the regimen if their condition is stable. If exacerbations persist, escalation to triple therapy with ICS+LABA+LAMA is recommended. For patients with COPD who are at high risk of pulmonary infection, including mycobacterial infection, withdrawal of ICS and a switch to dual bronchodilator therapy should be considered to reduce the risk of further infections. (1B/strong recommendation)Question 11: What are the indications for biologic therapy in patients with COPD?Recommendation 11: For patients who continue to experience recurrent exacerbations despite ICS+LABA+LAMA therapy, inhaled medication use, comorbidities and other contributing factors should be assessed, and biologic therapy should be selected on an individualized basis according to features such as the peripheral blood eosinophil count and the presence of chronic bronchitis. (1B/conditional recommendation)Question 12: How should an inhaler device be selected according to individual patient characteristics?Recommendation 12: The most appropriate inhaler device and medication should be selected according to whether the patient has adequate inspiratory flow, hand-mouth coordination, and the ability to inhale independently, as well as the characteristics of the device and medication. Training in inhaler technique and individualized assessment should be reinforced. (4/strong recommendation)Question 13: How should pulmonary rehabilitation be implemented for patients with COPD?Recommendation 13: Dynamic pulmonary rehabilitation assessment is recommended before treatment and at different stages during treatment, including clinical, functional, nutritional, and psychological assessments. Pulmonary rehabilitation should be initiated as early as possible in patients with stable COPD who have no absolute contraindications. For patients with acute exacerbations of COPD, pulmonary rehabilitation should be provided early during hospitalization and after discharge. An individualized rehabilitation prescription should be developed according to assessment findings and may include airway clearance techniques, breathing training, aerobic and resistance exercise, positioning, and respiratory support. (1A/strong recommendation)Question 14: What are the indications and treatment regimen for oxygen therapy in stable COPD?Recommendation 14: Long-term oxygen therapy is recommended for patients with COPD and severe resting hypoxemia, defined as either (1) PaO2≤55 mmHg(1 mmHg=0.133 kPa) or SpO2≤88% at rest, or (2) PaO2 of 55-60 mmHg or SpO2 of 88%-89% at rest together with pulmonary hypertension, peripheral edema suggestive of congestive heart failure, or polycythemia (hematocrit>55%). Oxygen should be administered for at least 15 h/day to maintain PaO2 ≥60 mmHg and/or SpO2 ≥90%. (1B/strong recommendation)Question 15: What are the indications for noninvasive ventilation in stable COPD?Recommendation 15: Long-term noninvasive ventilation (NIV) is suggested for patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, or for those with persistent daytime hypercapnia (PaCO2>53 mmHg). (1B/strong recommendation)Question 16: Which pharmacological and nonpharmacological interventions can reduce mortality in patients with COPD?Recommendation 16: Smoking cessation, pharmacotherapy (fixed-dose triple therapy), and nonpharmacological interventions, including pulmonary rehabilitation, long-term oxygen therapy, noninvasive ventilation, and surgical lung volume reduction, are recommended to reduce mortality in patients with COPD. (1B/strong recommendation)Question 17: How should bronchoscopic interventional therapies be selected for patients with COPD?Recommendation 17: Bronchoscopic interventions, including endobronchial valves and thermal vapor ablation, are recommended for selected patients with advanced emphysema and COPD. (1B/conditional recommendation)Question 18: What are the indications for lung transplantation in patients with COPD?Recommendation 18: For patients with very severe COPD (progressive disease with a BODE index of 7-10 who are not candidates for lung volume reduction surgery), referral for lung transplantation may be considered if at least one of the following is present: (1) a history of hospitalization for an acute hypercapnic exacerbation (PaCO2>50 mmHg); (2) pulmonary hypertension and/or cor pulmonale despite oxygen therapy; or (3) FEV₁<20% predicted together with DLCO<20% predicted or homogeneous emphysema. (3B/conditional recommendation)Question 19: How should systemic corticosteroids be used for acute exacerbations of COPD?Recommendation 19: For moderate or severe acute exacerbations of COPD, low-dose, short-course systemic corticosteroid therapy is suggested; routine prolongation of treatment or use of high-dose systemic corticosteroids is not recommended. Nebulized budesonide may be considered as an alternative for patients with contraindications to systemic corticosteroids or a high risk of adverse reactions. (Very low-quality evidence/weak recommendation)Question 20: How should high-flow nasal cannula oxygen therapy be used in the treatment of acute exacerbations of COPD?Recommendation 20: High-flow nasal cannula (HFNC) oxygen therapy is suggested for patients with an acute exacerbation of COPD who have persistent hypoxemia, cannot tolerate NIV or have contraindications to NIV, require sequential oxygen therapy after NIV, or require prevention of reintubation after extubation. In patients with acute hypercapnic respiratory failure who meet the indications for NIV, HFNC should not replace NIV as the preferred initial treatment. (1B/conditional recommendation)Question 21: What are the indications for noninvasive ventilation in the treatment of acute exacerbations of COPD?Recommendation 21: NIV is recommended for patients with an acute exacerbation of COPD who have any of the following: (1) respiratory acidosis (PaCO2 ≥6.0 kPa or 45 mmHg and arterial pH≤7.35); (2) severe dyspnea with clinical signs of respiratory muscle fatigue and/or increased work of breathing, such as use of accessory respiratory muscles, paradoxical thoracoabdominal motion, or intercostal retraction; (3) persistent hypoxemia despite oxygen therapy; or (4) a need for sequential invasive-noninvasive mechanical ventilation. (1A/strong recommendation)Question 22: What measures are recommended to prevent acute exacerbations of COPD?Recommendation 22: After an acute exacerbation, the management plans for COPD and its comorbidities should be evaluated, and appropriate measures should be implemented to prevent further exacerbations, particularly peri-discharge management, long-term standardized pharmacotherapy, smoking cessation, vaccination, and nonpharmacological interventions such as pulmonary rehabilitation. (4/strong recommendation). 《慢性阻塞性肺疾病诊治指南(2026年修订版)》由中华医学会呼吸病学分会慢性阻塞性肺疾病(简称慢阻肺病)学组和中国医师协会呼吸医师分会慢阻肺病学组组织制订。在2021年版指南基础上,本次修订结合近5年国内外循证医学证据和我国慢阻肺病防治实践,对疾病定义、病因与发病机制、病例发现、诊断与综合评估、稳定期管理、急性加重诊治、共病管理及未来研究方向进行了全面更新。指南主要采用GRADE方法,并结合牛津循证医学中心证据分级体系,对证据质量进行评价并形成推荐意见,围绕22个临床问题提出可操作的诊疗建议。指南旨在促进我国慢阻肺病的早期识别、规范诊疗和全程管理,提高我国慢阻肺病诊疗规范化水平,降低疾病负担。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese guidelines for the diagnosis and management of chronic obstructive pulmonary disease (2026 revision)]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42933872. doi:10.3760/cma.j.cn112147-20260817-00487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。